Tuesday, 1 November 2016

Antibodies in Lisbon

Here is ProfG planned talk for today at the Protein & Antibody 
Engineering Summit in Lisbon

Due to a diary issue, ProfG is in clinic today and therefore Prof. Baker will be giving the lecture.

Overview on the Current Antibody Treatment of Multiple
Sclerosis Gavin Giovannoni, MBBCh, Ph.D., FCP (Neurol., SA), FRCP, FRCPath,Professor, Neurology, Centre for Neuroscience and Trauma, Barts and the  London School of Medicine and Dentistry

Multiple sclerosis is a putative autoimmune disease of the central nervous system that is characterised pathologically by inflammation, demyelination and variable degrees of axonal loss. Numerous immunomodulatory therapies have been licensed, or are in late stage development, to treat multiple sclerosis including several monoclonal antibodies. Dissecting out the mode of action of the targeted monoclonal antibodies is providing interesting insights into the pathogenesis of MS.


  1. The first slide says "commonest NON-disabling disease". It seems to be a typo, isn't it?

  2. Thanks Commonest non traumatic disabling disease of young adults. Thanks but I have a different slide. I can't do 65 slides in 25minutes.


Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.